Aldeyra Therapeutics, Inc. (ALDX) is awaiting a key FDA decision on March 16, 2026, for its drug candidate Reproxalap, proposed for the treatment of dry eye disease.
Reproxalap is a first-in-class small-molecule modulator of reactive aldehyde species (RASP), which are elevated in ocular inflammation. The drug is designed to reduce symptoms like ocular discomfort and redness in patients with dry eye disease- a condition affecting millions and often under-treated.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com